MAPRx Comments on 2026 Part D Proposed Rule Regarding Anti-Obesity Medication Coverage

MAPRx strongly supports CMS’ proposal to permit coverage of anti-obesity medications to treat obesity for appropriate indications. AOMs are a critical component of the continuum of obesity care. Read our Comment Letter